Could a diabetes drug stop AFib from coming back?
NCT ID NCT06528262
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether enavogliflozin, a drug originally for diabetes, can prevent atrial fibrillation (AF) from returning after a catheter ablation procedure in people with AF and heart failure. About 390 adults will receive either the drug or a placebo daily for a year. The main goal is to see if the drug reduces AF recurrence between 3 months and 1 year after the procedure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Enavogliflozin (a type of SGLT2 inhibitor drug, originally used for diabetes)
- What this could lead to
- If it works, this could provide a new way to prevent atrial fibrillation from coming back after a common heart procedure, especially for people with heart failure.
- What could go wrong
- This is a Phase 4 trial, but it is still relatively small (390 people) and only tests one drug. Previous studies were mostly in people with diabetes, so results may not apply to everyone. The drug may not reduce recurrence significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 390 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 84 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults aged 19 to under 85 2. Patients who consent to participate in the study and can be followed up during the study 3. Patients with AF and heart failure who have undergone atrial fibrillation catheter ablation within the last three months or are scheduled to undergo the procedure Exclusion Criteria: 1. Under 19 or over 85 years old 2. Patients who have participated in another clinical trial within the last three months 3. Life expectancy of less than one year 4. Pregnant or breastfeeding women 5. Currently being treated with an SGLT-2 inhibitor 6. Three or more urinary or genital infections within the last year 7. Uncontrolled hypertension: systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 110mmHg 8. Systolic blood pressure \< 90mmHg 9. Acute cardiovascular event within the last 12 weeks 10. Severe valvular disease or presence of artificial valves 11. Renal impairment (eGFR CKD-EPI \< 60 ml/min/1.73m²) 12. Clinically confirmed liver dysfunction 13. Uncontrolled thyroid dysfunction 14. Patients with active cancer (including those undergoing treatment) or history of cancer within the last five years at the time of screening; however, borderline cancers are not excluded if successfully treated and recurrence-free for 2-3 years. 15. Continuous use of oral prednisolone at 10mg/day or equivalent, or higher doses of steroids, within the last month 16. Patients with hypersensitivity or history of hypersensitivity to the active or inactive ingredients of this drug 17. Patients with type 1 diabetes or diabetic ketoacidosis 18. History of alcohol or substance abuse 19. Women of childbearing potential who do not agree to use adequate contraception during the clinical trial period
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Severance Hospital
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart hole or stroke trigger? global registry tracks who gets closure and what happens next
- Two ways to quiet a racing heart: trial pits hybrid ablation against standard catheter treatment
- Stroke's hidden heart rhythm clue under investigation
- Suture device may get heart patients walking sooner after leg vein procedures
- Two ways to catch a hidden heart rhythm after stroke
- Can an implanted heart monitor catch hidden irregular heartbeats after stroke?